Jennie Best (Amylin Pharmaceuticals, San Diego, California) and colleague used data of medical insurance LifeLink claims database to assess whether treatment of 'type 2' diabetes by twice daily exenatide injections leads to reduced CVD events compared with other antidiabetic medications.
Jennie Best (Amylin Pharmaceuticals, San Diego, California) and colleagues used data from the LifeLink medical insurance claims database to assess whether treatment of Type 2 diabetes with twice-daily exenatide injections leads to reduced CVD event rates compared with other antidiabetic medications.